Nicolas Warin
Novartis (Switzerland)(CH)Novartis Institutes for BioMedical Research
Publications by Year
Research Areas
Chemical Synthesis and Analysis, PI3K/AKT/mTOR signaling in cancer, Synthesis and Biological Evaluation, Protein Kinase Regulation and GTPase Signaling, Microtubule and mitosis dynamics
Most-Cited Works
- → N-(5-Chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5- (tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a Novel, Highly Selective, Orally Available, Dual-Specific c-Src/Abl Kinase Inhibitor(2006)362 cited
- → Discovery, Synthesis, and in Vivo Activity of a New Class of Pyrazoloquinazolines as Selective Inhibitors of Aurora B Kinase(2007)273 cited
- → Discovery of Roblitinib (FGF401) as a Reversible-Covalent Inhibitor of the Kinase Activity of Fibroblast Growth Factor Receptor 4(2020)110 cited
- → Discovery of Novel and Potent Thiazoloquinazolines as Selective Aurora A and B Kinase Inhibitors(2006)92 cited
- → JDQ443, a Structurally Novel, Pyrazole-Based, Covalent Inhibitor of KRASG12C for the Treatment of Solid Tumors(2022)90 cited
- → Discovery of (R)-8-(1-(3,5-Difluorophenylamino)ethyl)-N,N-dimethyl-2-morpholino-4-oxo-4H-chromene-6-carboxamide (AZD8186): A Potent and Selective Inhibitor of PI3Kβ and PI3Kδ for the Treatment of PTEN-Deficient Cancers(2014)86 cited
- → Inhibitors of epidermal growth factor receptor tyrosine kinase: Novel C-5 substituted anilinoquinazolines designed to target the ribose pocket(2005)40 cited
- → Structure–activity relationship of a series of non peptidic RGD integrin antagonists targeting α5β1: Part 1(2012)9 cited
- → Structure–activity relationship of a series of non peptidic RGD integrin antagonists targeting α5β1: Part 2(2012)9 cited
- → Discovery of a series of 8-(2,3-dihydro-1,4-benzoxazin-4-ylmethyl)-2-morpholino-4-oxo-chromene-6-carboxamides as PI3Kβ/δ inhibitors for the treatment of PTEN-deficient tumours(2016)7 cited